Even the largest pharma companies will need to step outside their sector and collaborate with other organisations, according to new research by PwC.

Sanofi-aventis has opened its BIOLAUNCH project in France, where it plans to invest €200 million to develop biotech expertise.

It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.

With investors keeping their money in their pockets, and the IPO window nailed shut, the 33 year-old model of biotech funding is outdated, says a new report.